Oculis says PREDICT-1 dry eye trial of licaminlimab targets topline data around year-end
Bitget2026/10/07 06:02Oculis flagged licaminlimab as a lead program ahead of an Eyecelerator @ AAO 2026 presentation on Oct. 8. Topline results from the PREDICT-1 registrational symptoms trial are expected around year-end, not yet presented. The readout is positioned as a key step toward a genotype-guided treatment approach for TNFR1-mediated dry eye disease. Oculis also plans to sponsor AAO’s Neuro-Ophthalmology Subspecialty Day on Oct. 9, underscoring its strategic focus in the field. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oculis Holding AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610070200OMX_____CNEWS_EN_GNW1001276646_en) on October 07, 2026, and is solely responsible for the information contained therein.
- Oculis flagged licaminlimab as a lead program ahead of an Eyecelerator @ AAO 2026 presentation on Oct. 8.
- Topline results from the PREDICT-1 registrational symptoms trial are expected around year-end, not yet presented.
- The readout is positioned as a key step toward a genotype-guided treatment approach for TNFR1-mediated dry eye disease.
- Oculis also plans to sponsor AAO’s Neuro-Ophthalmology Subspecialty Day on Oct. 9, underscoring its strategic focus in the field.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Deutsche Bank made significant Q3 purchases of midstream AI application stocks: the three major cloud giants saw increased holdings, with Palantir (PLTR.US) and Salesforce (CRM.US) also favored.
Deutsche Bank has submitted its third quarter 13F holdings report for the period ending September 30, 2026.
Pendle Bridge integrates with BungeeExchange, supporting cross-chain transfers across 13 networks
Barclays significantly increased holdings in Tesla (TSLA.US) and Intel (INTC.US) in Q3, and bought Nasdaq ETF options for hedging
According to disclosures by the U.S. Securities and Exchange Commission (SEC), Barclays has submitted its third-quarter holdings report (13F) as of September 30, 2026.
Crypto prices
More
